07:00 , Jun 27, 2011 |  BC Week In Review  |  Clinical News

MDX-1097: Phase II ongoing

Immune System Therapeutics said a DSMB recommended enrollment of an additional 14 patients in an open-label, Australian Phase II trial after an interim review showed 1 response in 6 patients, with no treatment-related toxicities. The...
07:00 , Apr 27, 2009 |  BC Week In Review  |  Clinical News

MDX-1097: Phase I started

Immune System (formerly PacMab Ltd.) began an open-label, single ascending-dose, Australian Phase I trial to evaluate 0.3, 1.0, 3.0, 10 or 30 mg/kg of intravenous MDX-1097 in 15 patients. The company partnered with Medarex...
08:00 , Oct 31, 2005 |  BioCentury  |  Finance

Ebb & Flow

Cerimon's $70 million series A round probably turned some heads last week, as the company's lone products are topical formulations of diclofenac, an NSAID that's rather long of tooth. However, the company's directors and investors...